^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + gefitinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
Published date:
07/09/2020
Excerpt:
...we report a patient diagnosed with lung adenocarcinoma harboring EGFR 19Del/T790M/in trans-C797S mutations with co-occurring CTNNB1 alteration showing a negative response to combination therapy with first- and third-generation TKIs….the patient started to receive gefitinib combined with osimertinib as further-line treatment in February, 2020. However, the sudden emerging and rapid enlarged mass on his right neck saw him admitted to our hospital again on March 10, 2020. Cervical magnetic resonance imaging (MRI) showed the emerging lesion, which was finally confirmed with pathologic findings by biopsy (Figure 2).
DOI:
10.2147/OTT.S262594
